dm+d

29905911000001105

Articles

Using COVID-19 vaccines in patients with anticoagulation and bleeding disorders

7 January 2021Information on use of the vaccine in patients who are receiving anticoagulants or have a bleeding disorder is given below.

Consultations (counselling) about oral anticoagulants apixaban, dabigatran, edoxaban, rivaroxaban and warfarin for patients with aphasia

8 October 2020These resources are designed to support all clinicians who communicate with patients prescribed warfarin  or direct oral anticoagulants (DOACs), formerly known as novel  oral anticoagulants…

Suggestions for Therapeutic Drug Monitoring in Adults in Primary Care

29 September 2020This document is intended to support local discussions on how to monitor commonly prescribed high risk medicines in primary care.    The monitoring parameters cited…

Safety in Lactation: Drugs for thromboembolic disorders

18 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Oral anticoagulants The coumarin anticoagulants, warfarin…

Anticoagulation for Atrial Fibrillation ‘Perfect’

26 May 2020Anticoagulation is key to reducing the risk of stroke in atrial fibrillation (AF).  However ensuring that the anticoagulant is prescribed at the correct dose for…
Search Articles

Lactation Safety Information

No
Warfarin
Direct activated factor X inhibitor
No published evidence of safety
20 October 2016

New Medicines

Lixiana (EU), Savaysa (US)Treatment of venous thromboembolism (VTE) associated with cancer (other than basal cell or squamous cell carcinoma of the skin)

Information

Lixiana (EU), Savaysa (US)
Licence extension / variation
Daiichi Sankyo
Daiichi Sankyo

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Factor Xa inhibitor
VTE is a major cause of morbidity and mortality in pts with cancer, with an annual incidence of up to 20% depending on the cancer type, background risk and time since diagnosis. Pts with cancer who receive chemotherapy have a 4- to 7-fold higher risk of developing VTE due to the presence of multiple risk factors. In addition, patients with cancer and VTE have a lower survival rate than those without VTE. [1]
Treatment of venous thromboembolism (VTE) associated with cancer (other than basal cell or squamous cell carcinoma of the skin)
Oral